Approved by the FDA in July 2023, Lequembi is a monoclonal antibody that does not offer a cure to the disease but has shown promise in slowing cognitive decline in early stage Alzheimer’s patients.
The approval process and regimen include multiple diagnostic tests and insurance has been an significant obstacle, with some coverage denials and delays because of the drugs high cost and novelty.
Biogen and Eisai are working on more accessible forms of the drug, including a maintenance dose and a subcutaneous version to ease the burden on patients and broaden its use.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.